Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1826 + carboplatin
- Development stage
- Unknown
- Lead developer
- Suzhou Suncadia Biopharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**SHR-1826 + carboplatin** is a combination of an antibody-drug conjugate (ADC) targeting c-Met (SHR-1826) and the cytotoxic chemotherapy agent carboplatin, investigated for the treatment of advanced solid tumors. SHR-1826 acts as a c-Met inhibitor; the antibody component targets the c-Met receptor, which is overexpressed in certain cancers, and delivers a cytotoxic payload to the cancer cells[1][5][6]. Carboplatin, a platinum-based agent, induces DNA damage leading to apoptosis in rapidly dividing cells. The combination leverages targeted therapy and enhanced cytotoxicity, aiming for synergistic anti-tumor efficacy, particularly in solid tumors such as non-small cell lung cancer and hepatocellular carcinoma[1][8][9]. Development is led by Suzhou Suncadia Biopharmaceuticals.
- Other names
- SHR-1826 + carboplatin
02
Targets
DNAMET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on SHR-1826 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1826 + carboplatin.